RMRizwan Masood

Rizwan Masood

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rizwan Masood has a total of 46 co-authors. Here are the top co-authors by number of shared publications:

  • Uttam K. Sinha

    Department of Otolaryngology—Head and Neck Surgery, University of Southern California, Keck School of Medicine, Los Angeles, CA, USA

    3 shared publications
  • Christian Hochstim

    Department of Otolaryngology—Head and Neck Surgery, University of Southern California, Keck School of Medicine, Los Angeles, CA, USA

    2 shared publications
  • Diane Lynne Smith

    Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

    2 shared publications
  • Parkash S. Gill

    2 shared publications
  • SuTao Zhu

    University of Southern California Keck School of Medicine, USC/Norris Comprehensive Cancer Center, Los Angeles, CA, USA

    2 shared publications
  • Sutao Zhu

    Departments of Otolaryngology, Pathology, Keck School of Medicine of the University of Southern California, Los Angeles, CA

    2 shared publications

Latest Publications

  • Open Access

    A novel orthotopic mouse model of head and neck cancer and lymph node metastasis

    by R Masood, C Hochstim, B Cervenka, S Zu, S K Baniwal, V Patel, A Kobielak, U K Sinha

    Prognosis of head and neck squamous cell carcinoma (HNSCC) is largely determined by the extent of lymph node (LN) metastasis at diagnosis, and this appears to be controlled by cancer cell genetics. To examine the role of these genes in LN metastasis, we created a human-in-mouse orthotopic model of HNSCC and performed comparative microarray analysis of gene expression between populations of HNSCC cell lines derived before and after serial transplantation and in vivo metastasis in mice. Microarray analysis comparing the USC-HN3-GFP, USC-HN3-GFP-G1 and USC-HN3-GFP-G2 cell lines identified overexpression of genes implicated in epithelial-to- mesenchymal transition and the formation of cancer stem cells, including CAV-1, TLR-4 (Toll-like receptor 4), MMP-7 (matrix metalloproteinase 7), ALDH1A3, OCT-4 and TRIM-29. Ingenuity Pathway Analysis confirmed upregulation of respective gene signaling pathways in the USC-HN1-GFP-G2 cell line. Patient HNSCC samples from advanced stages overexpressed ALDH1A3, CAV-1 and MMP-7. Our results show that CAV-1, TLR-4, MMP-7, ALDH1A3, OCT-4 and TRIM-29 have increased expression in HNSCC cells selected for an enhanced metastatic phenotype and suggest that these genes may have an important role in the metastatic potential of HNSCC cells. Inhibition of these genes may therefore have prognostic and therapeutic utility in HNSCC.


  • Gold nanorod–sphingosine kinase siRNA nanocomplexes: a novel therapeutic tool for potent radiosensitization of head and neck cancer

    by Rizwan Masood, Indrajit Roy, Sutao Zu, Christian Hochstim, Ken-Tye Yong, Wing-Cheung Law, Hong Ding, Uttam K. Sinha, Paras N. Prasad

    A unique theragonostic approach of gene delivery is based on a synergistic combination of gold nanorods (GNRs) and small interfering RNA (siRNA) nanoplexes.


  • Quantum Dot Nanoparticle Targeting of Claudin-4 as a Biomarker of Head and Neck Squamous Cell Carcinoma

    by Vaninder K. Dhillon, Jacqueline E. Weinstein, Sutao Zhu, Rizwan Masood, Uttam K. Sinha

  • Increased radiation sensitivity of head and neck squamous cell carcinoma with sphingosine kinase 1 inhibition

    by Uttam K. Sinha, Victor J. Schorn, Christian Hochstim, Steven B. Chinn, Sutao Zhu, Rizwan Masood

    Background: Sphingosine kinase 1 (SphK1) is an important regulator of apoptosis, survival, and proliferation in cancer cells. SphK1 expression in head and neck squamous cell cancer (HNSCC) cell lines and tumor tissue was assessed, and the efficacy of SphK1 knockdown in increasing tumor radiosensitivity was evaluated in vitro and in vivo.Methods: Expression of SphK1 was determined by immunohistochemistry, Western blot, and real‐time polymerase chain reaction (RT‐PCR) in 34 prospectively collected HNSCC tumor samples. HNSCC cell lines squamous cell carcinoma (SCC)‐15 and SCC‐25 were treated with SphK1 inhibitor SKI‐II and siRNA targeting SphK1 with and without radiation, and the cell viability was assessed. SCC‐15 cells with and without transfection of SphK1 siRNA were then injected into athymic nude mice to develop tumor xenografts, and these 2 groups were further divided into 1 group that received radiation and 1 group that did not. Tumor size was measured over 18 days, when the animals were killed and the tumors were evaluated by immunohistochemistry.Results: SphK1 is found in both HNSCC cell lines and human tumor samples, with higher expression correlated with advanced tumor stage, nodal involvement, and recurrence. In vitro, both SCC‐15 and SCC‐25 were found to be radioresistant; however, they were sensitized by administration of SKI‐II and transfection with siRNA targeting SphK1. In vivo, SphK1‐siRNA transfected xenografts were decreased in size compared with both nonradiated control and radiated control mice, whereas mice with both SphK1‐siRNA and radiation treatment showed a synergistic reduction in tumor volume. Histopathologic analysis demonstrated a decreased proliferative state in SphK1‐siRNA transfected tumors.Conclusion: SphK1 is upregulated in HNSCC, and inhibition of SphK1 sensitizes HNSCC to radiation‐induced cytotoxicity. © 2010 Wiley Periodicals, Inc. Head Neck, 2011


  • Open Access

    Establishment and Characterization of a Novel Head and Neck Squamous Cell Carcinoma Cell Line USC-HN1

    by Daniel J Liebertz, Melissa G Lechner, Rizwan Masood, Uttam K Sinha, Jing Han, Raj K Puri, Adrian J Correa, Alan L Epstein

    Background: Head and neck squamous cell carcinoma (HNSCC) is an aggressive and lethal malignancy. Publically available cell lines are mostly of lingual origin, or have not been carefully characterized. Detailed characterization of novel HNSCC cell lines is needed in order to provide researchers a concrete keystone on which to build their investigations. Methods: The USC-HN1 cell line was established from a primary maxillary HNSCC biopsy explant in tissue culture. The immortalized cells were then further characterized by heterotransplantation in Nude mice; immunohistochemical staining for relevant HNSCC biomarkers; flow cytometry for surface markers; cytogenetic karyotypic analysis; human papillomavirus and Epstein-Barr virus screening; qRT-PCR for oncogene and cytokine analysis; investigation of activated, cleaved Notch1 levels; and detailed 35,000 gene microarray analysis. Results: Characterization experiments confirmed the human HNSCC origin of USC-HN1, including a phenotype similar to the original tumor. Viral screening revealed no HPV or EBV infection, while western blotting displayed significant upregulation of activated, cleaved Notch1. Conclusions: USC-HN1, a novel immortalized cell line has been derived from a maxillary HNSCC. Characterization studies have shown that the cell line is of HNSCC origin and displays many of the same markers previously reported in the literature. USC-HN1 is available for public research and will further the investigation of HNSCC and the development of new therapeutic modalities.


  • Open Access

    The Significance of EphB4 and EphrinB2 Expression and Survival in Head and Neck Squamous Cell Carcinoma

    by Eric J. Yavrouian, Uttam K. Sinha, Dale H. Rice, Muhammad T. Salam, Parkash S. Gill, Rizwan Masood

    Head and neck squamous cell carcinoma (HNSCC) is an epithelial cancer that arises in the mucosa of the upper aerodigestive tract.1 It commonly affects the oral cavity, oropharynx, hypopharynx, and larynx.2 Head and neck squamous cell carcinoma is the sixth most common cancer worldwide, comprising about 4% of all malignant neoplasms, with 900 000 cases worldwide each year.3 In the United States, it was estimated that in 2008 there would be 48 000 cases and 11 000 deaths from the disease. Men are significantly more affected than women, with increased incidence and mortality among African American men.4 Important risk factors associated with the development of HNSCC are tobacco and alcohol use; therefore, abstinence from smoking and drinking is the best mode of prevention.5


  • Open Access

    Natural killer cell cytolytic activity is necessary for in vivo antitumor activity of the dipeptide L‐glutamyl‐L‐tryptophan

    by D. Lynne Smith, Jie Cai, SuTao Zhu, Wen Wei, Jon Fukumoto, Sanjai Sharma, Rizwan Masood, Parkash S. Gill

    A dipeptide, L-glutamyl L-tryptophan (L-glu-L-trp), was identified in a screen for immunomodulators in the soluble fraction of the thymus. L-glu-L-trp inhibits tumor growth in mice without showing direct cellular toxicity in a variety of human tumor cell lines. L-glu-L-trp antitumor activity in vivo requires the presence of natural killer (NK) cells. Defective trafficking of cytoplasmic granules caused by the Lyst mutation also resulted in loss of antitumor activity of the dipeptide. The effect of L-glu-L-trp on tumor growth in mice with targeted gene mutations demonstrated the absolute requirement for perforin for antitumor activity. The requirement of 2 major modulators of NK cell activity, gamma interferon (IFNγ) and interleukin (IL)-12, were also tested. L-glu-L-trp had full antitumor activity in IFNγ knockout mice, but had significantly diminished activity in IL-12 knockout mice. These data show that L-glu-L-trp antitumor activity in mice is dependent on cytolytic cell activity of NK or NKT cells. L-glu-L-trp in vivo regulates NK cell function independent of IFNγ but partly dependent on IL-12.


  • Open Access

    Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF‐C autocrine loops

    by Rizwan Masood, Ajay Kundra, SuTao Zhu, Guangbin Xia, Pierluigi Scalia, D. Lynne Smith, Parkash S. Gill

    Malignant mesothelioma (MM) is a locally aggressive tumor that originates from the mesothelial cells of the pleural and sometimes peritoneal surface. Conventional treatments for MM, consisting of chemotherapy or surgery give little survival benefit to patients, who generally die within 1 year of diagnosis. Hence, there is an urgent need for the development of alternative therapies. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for MM. The closely related molecule, VEGF‐C, is also implicated in malignant mesothelioma growth. VEGF‐C and its cognate receptor VEGFR‐3 are co‐expressed in mesothelioma cell lines. A functional VEGF‐C autocrine growth loop was demonstrated in mesothelioma cells by targeting VEGF‐C expression and binding to VEGFR‐3. The ability of novel agents that reduce the levels of VEGF and VEGF‐C to inhibit mesothelioma cell growth in vitro was assessed. Antisense oligonucleotide (ODN) complementary to VEGF that inhibited VEGF and VEGF‐C expression simultaneously specifically inhibited mesothelioma cell growth. Similarly, antibodies to VEGF receptor (VEGFR‐2) and VEGF‐C receptor (VEGFR‐3) were synergistic in inhibiting mesothelioma cell growth. In addition, a diphtheria toxin‐VEGF fusion protein (DT‐VEGF), which is toxic to cells that express VEGF receptors was very effective in inhibiting mesothelioma cell growth in vitro. These results indicate that targeting VEGF and VEGF‐C simultaneously may be an effective therapeutic approach for malignant mesothelioma.


  • VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer

    by Hubert G. Hotz, Oscar J. Hines, Rizwan Masood, Birgit Hotz, Parkash S. Gill, Howard A. Reber